GGrantIndex
← Leaderboards

Adam Joel Bass

Dana-Farber Cancer Inst

Google Scholar ↗PubMed ↗ORCID ↗
$9,339,125
Attributed
$12,227,436
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.8M · FY2008–23
$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$23,477,355 · 13

By mechanism

P50$9,099,897 · 5
R01$8,281,238 · 4
U54$4,343,905 · 1
P01$827,195 · 1
K08$774,319 · 1
P30$150,801 · 1

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Top investigators on “Genomics”

Research focus

GenomicsMalignant NeoplasmsProgramsMutationCollaborationsResearch PersonnelBaseGeneticTechnologyTumorInnovationGenomeFundingCancer CenterGenesOncogenesEsophageal AdenocarcinomaEventOverexpressionCessation Of LifeCellsDana-Farber Cancer InstituteMalignant Neoplasm Of EsophagusPhosphotransferases

Grant awards (46)

Project 4 - Characterizing and Overcoming Resistance to ERBB2 Directed Therapy in Metastatic Gastric and Esophageal Adenocarcinoma$328,658
P50 · FY2023 · CA · contact PI
Core A - Administrative Core$191,595
P50 · FY2023 · CA · contact PI
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$166,357
P01 · FY2023 · CA · contact PI
Core A - Administrative Core$213,734
P50 · FY2022 · CA · contact PI
The Role of RHOA in Diffuse Gastric Cancer$819,369
R01 · FY2021 · CA · contact PI
Project 4 - Characterizing and Overcoming Resistance to ERBB2 Directed Therapy in Metastatic Gastric and Esophageal Adenocarcinoma$333,633
P50 · FY2021 · CA · contact PI
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$167,012
P01 · FY2021 · CA · contact PI
Program 32: Gastrointestinal Malignancies$73,983
P30 · FY2021 · CA · contact PI
Core A - Administrative Core$64,440
P50 · FY2021 · CA · contact PI
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma$939,989
U54 · FY2020 · CA
The Role of RHOA in Diffuse Gastric Cancer$677,302
R01 · FY2020 · CA · contact PI
Project 4 - Characterizing and Overcoming Resistance to ERBB2 Directed Therapy in Metastatic Gastric and Esophageal Adenocarcinoma$288,629
P50 · FY2020 · CA · contact PI
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma$230,473
U54 · FY2020 · CA
Core A - Administrative Core$189,465
P50 · FY2020 · CA · contact PI
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$167,612
P01 · FY2020 · CA · contact PI
Program 32: Gastrointestinal Malignancies$73,870
P30 · FY2020 · CA · contact PI
Program 32: Gastrointestinal Malignancies$2,948
P30 · FY2020 · CA · contact PI
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer$2,450,827
P50 · FY2019 · CA · contact PI
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma$1,026,103
U54 · FY2019 · CA
The Role of RHOA in Diffuse Gastric Cancer$656,983
R01 · FY2019 · CA · contact PI
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers$375,415
R01 · FY2019 · CA · contact PI
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma$373,325
R01 · FY2019 · CA · contact PI
Project 4 - Characterizing and Overcoming Resistance to ERBB2 Directed Therapy in Metastatic Gastric and Esophageal Adenocarcinoma$372,636
P50 · FY2019 · CA · contact PI
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$326,214
P01 · FY2019 · CA · contact PI
Core A - Administrative Core$211,093
P50 · FY2019 · CA · contact PI
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma$1,063,190
U54 · FY2018 · CA
The Role of RHOA in Diffuse Gastric Cancer$677,302
R01 · FY2018 · CA · contact PI
In Vivo Laser Capture Microdissection$666,768
R01 · FY2018 · EB
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers$387,027
R01 · FY2018 · CA · contact PI
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma$384,872
R01 · FY2018 · CA · contact PI
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER$2,293,187
P50 · FY2017 · CA · contact PI
Early Targets in Progression of Barrett's Esophagus to Esophageal Adenocarcinoma$1,084,150
U54 · FY2017 · CA
In Vivo Laser Capture Microdissection$647,377
R01 · FY2017 · EB
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers$387,027
R01 · FY2017 · CA · contact PI
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma$384,872
R01 · FY2017 · CA · contact PI
SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER$2,162,000
P50 · FY2016 · CA · contact PI
In Vivo Laser Capture Microdissection$687,869
R01 · FY2016 · EB
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers$387,027
R01 · FY2016 · CA · contact PI
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma$384,872
R01 · FY2016 · CA · contact PI
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma$383,831
R01 · FY2015 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$140,940
K08 · FY2012 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$140,940
K08 · FY2011 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$140,940
K08 · FY2010 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$140,940
K08 · FY2009 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$69,619
K08 · FY2009 · CA · contact PI
Genome Discovery and Validation in Upper Gastrointestinal Carcinomas$140,940
K08 · FY2008 · CA · contact PI